SAFETY AND EFFICACY IN NVAF PATIENTS AFTER SUCCESSFUL PCI IN THE ENTRUST-AF PCI TRIAL
Once-daily LIXIANA® plus a P2Y12 inhibitor was non-inferior to a triple therapy with well-managed VKA regarding the risks of major or CRNM bleeding events at 12 months and numerically lower in bleeding events vs the VKA-based regimen in NVAF patients after successful PCI.1
PRIMARY OUTCOME EVENTS OF MAJOR OR CRNMc BLEEDING (INTENTION-TO-TREAT POPULATION: N=1506)
a Patients taking LIXIANA® 60 mg as standard dose and those dose-reduced to 30 mg.
b Vitamin K antagonist. Median time-in-therapeutic range (TTR): 63.1%.
c Clinically relevant non-major.
d Hazard ratio.
e Confidence interval.
A triple therapy with well-managed VKA was lower in bleeding events before day 14 vs once-daily LIXIANA® plus a P2Y12 inhibitor followed by a significant reduction in the rate of the bleeding outcome favouring the LIXIANA regimen in NVAF patients after successful PCI.1
LANDMARK ANALYSIS FOR THE PRIMARY OUTCOME OF MAJOR OR CRNMc BLEEDING WITH A LANDMARK AT 14 DAYS
a Patients taking LIXIANA® 60 mg as standard dose and those dose-reduced to 30 mg.
b Vitamin K antagonist. Median time-in-therapeutic range (TTR): 63.1%.
c Clinically relevant non-major.
d Hazard ratio.
e Confidence interval.
Once-daily LIXIANA® plus a P2Y12 inhibitor showed a similar rate of the main efficacy outcome vs a triple therapy regimen with well-managed VKA in NVAF patients after successful PCI.1
MAIN EFFICACY OUTCOME (COMPOSITE OF CV DEATH, STROKE, SYSTEMIC EMBOLIC EVENT, MYOCARDIAL INFARCTION, OR DEFINITE STENT THROMBOSIS)
a Patients taking LIXIANA® 60 mg as standard dose and those dose-reduced to 30 mg.
b Vitamin K antagonist. Median time-in-therapeutic range (TTR): 63.1%.
c Hazard ratio.
d Confidence interval.
